Nonsense Mutation Correction in Human Diseases: An Approach for Targeted Medicine

A Mutation That Silences a Protein

Nonsense mutations introduce a premature stop signal into a gene’s coding sequence. The result can be a truncated, nonfunctional protein and, in many cases, serious inherited disease. Nonsense Mutation Correction in Human Diseases: An Approach for Targeted Medicine examines this problem at the molecular level and follows it toward an emerging therapeutic goal: restoring the expression of genes that a nonsense mutation has effectively switched off.

Written by Hana Benhabiles, Jieshuang Jia, and Fabrice Lejeune, the book brings together genetics, RNA biology, and drug-discovery thinking. It is a specialized scientific reference rather than a general introduction, and it assumes a reader who is comfortable with molecular biology and clinical genetics.

From Premature Termination Codons to Disease

The opening chapter lays out the basic language of the field. It explains how an open reading frame normally begins and ends, what makes a stop codon premature, and why all nonsense mutations are premature termination codons while not all premature termination codons are nonsense mutations. Insertions, deletions, frameshifts, and splicing errors can also introduce a premature stop, and the book traces those events at DNA, RNA, and protein levels.

Frequency patterns of the three stop codons—UGA, UAG, and UAA—are discussed in both normal termination and nonsense mutation contexts. The text also connects these molecular details to the transition mutations that commonly create premature stops, giving readers a statistical and mechanistic view of how nonsense mutations arise.

Pre-mRNA Splicing and the Nonsense-Mediated mRNA Decay Pathway

A major portion of the book explores the quality-control system known as nonsense-mediated mRNA decay (NMD). Before a faulty mRNA can be translated into a harmful or useless protein, NMD can recognize and degrade it. The book examines the proteins involved, the exon junction complex–dependent model, and the model based on the distance between the stop codon and the position of poly(A) binding protein C1.

Additional coverage includes natural substrates of NMD, its regulation, and an UPF2/UPF3X-independent pathway. The discussion also considers pathologies associated with splicing defaults and with failures in NMD itself, showing why this quality-control mechanism matters beyond the laboratory.

Toward Targeted Correction of Nonsense Mutations

The final chapter turns to therapeutic strategy. If a premature stop codon causes a disease, one possible approach is to correct or bypass it so that the gene can produce a functional protein again. The authors frame this as a case of targeted therapy and discuss the search for molecules capable of rescuing expression of genes carrying nonsense mutations.

Their perspective is interdisciplinary. Chemistry, RNA biology, clinical genetics, and patient-focused research all enter the picture. The acknowledgments emphasize collaboration among research groups, academic and private laboratories, clinicians, and patient associations—an outlook that runs through the book’s treatment of targeted medicine.

Who This Book Is For

• Molecular biologists and geneticists studying RNA processing, NMD, or disease-causing mutations
• Clinical researchers and medical scientists interested in genetic disease mechanisms
• Pharmacologists and drug-discovery professionals exploring targeted therapeutic approaches
• Graduate students and advanced undergraduates in genetics, molecular biology, or biomedicine
• Readers who need a focused scientific treatment of nonsense mutation correction rather than a broad popular-science overview

A Specialized Reference for Genetic Medicine

Published in 2016 by Academic Press, an imprint of Elsevier, this book captures a research area in motion. It is detailed, citation-rich, and oriented toward readers who want to understand both the molecular machinery and the therapeutic possibilities. For anyone working at the intersection of RNA biology and inherited disease, it offers a structured path from the basic defect to the long-term goal of treatment.